Canagliflozin Reduced Urinary Bacteria in Laboratory Study
The diabetes medication demonstrated the ability to limit bacterial growth inside cells in a recent in vitro investigation.
Updated on Oct. 1, 2026 in Diabetes
Live Poll
Do you trust that new medical research is adequately addressing side effects of common diabetes drugs?
Researchers found that the SGLT2 inhibitor canagliflozin lowered the recovery of intracellular uropathogenic Escherichia coli and Salmonella Typhimurium in laboratory cell cultures. This discovery could eventually inform new approaches to managing recurrent urinary tract infections.
Why it matters
SGLT2 inhibitors like canagliflozin are known to increase the risk of urinary tract infections because they cause glucose to be excreted through urine. This study suggests these medications may possess unique properties that could eventually complement standard antibiotic treatments for these infections.
In an in vitro study, researchers measured bacterial burden, glucose uptake, and ATP levels in cultured uroepithelial and macrophage-like THP-1 cells. The findings showed that canagliflozin reduced intracellular recovery of pathogens compared to controls, though the effect was not seen in Caco-2 cells.
The details
The researchers exposed uroepithelial cell lines to uropathogenic Escherichia coli (UPEC) strains to observe how the drug altered the infection process. Canagliflozin interfered with the hemolytic activity of the bacterial toxin α-hemolysin, potentially reducing the ability of pathogens to survive within human cells. While other SGLT2 inhibitors also showed interference with this toxin, ipragliflozin demonstrated a significantly weaker effect on intracellular bacterial recovery.
Timeline
October 1, 2026: Findings were published regarding the effects of canagliflozin on bacterial recovery.
Health Landscape
The clinical management of SGLT2 inhibitor-associated urinary tract infections typically focuses on hygiene and monitoring during glucose-lowering therapy. This research adds a novel perspective by suggesting that these same drugs may eventually be repurposed to target the intracellular mechanisms of pathogens.
This research is currently limited to laboratory experiments and does not change how you should manage your current diabetes medication. If you are taking an SGLT2 inhibitor and experience symptoms of a urinary tract infection, always reach out to your physician to discuss appropriate testing and treatment.
The takeaway
While these laboratory results indicate that canagliflozin may have unexpected antimicrobial properties, it remains a medication primarily used for blood glucose management. Always consult your doctor before making any adjustments to your treatment plan or if you notice signs of an infection.
Further reading
Learn more about managing your care by visiting our Diabetes section.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that new medical research is adequately addressing side effects of common diabetes drugs?
